Develops antibody-based drugs for various diseases.
Dec 2025Revenue €9.01M/yrExpenses €63.0M/yr
No trendCash runway ≈ 6 months from Dec 2025
Figures by year
When will Innate Pharma be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Dec 2025, revenue was €9.01M and expenses €63.0M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | €9.01M | €63.0M | −€54.0M |
| Dec 2024 | €20.1M | €71.7M | −€51.6M |
| Dec 2023 | €61.6M | €74.3M | −€12.7M |
| Dec 2022 | €57.7M | €115M | −€57.4M |
| Dec 2021 | €24.7M | €72.5M | −€47.8M |
| Dec 2020 | €69.8M | €68.7M | €1.08M |
| Dec 2019 | €85.4M | €83.9M | €1.57M |
| Dec 2018 | €94.0M | €88.8M | €5.15M |
| Dec 2017 | €44.0M | €84.0M | −€40.0M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.